secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2023-06-22T23:59:59+00:00
Accession:  0000950170-23-029447
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon Therapeutics stockholders elect two Class I directors and ratify auditor
--------------------------------------------------------------------------------

- Michael Tomsicek elected Class I director with 17,527,002 votes for and 226,168 withheld.
- Charles Baum elected Class I director with 17,660,794 votes for and 91,113 withheld.
- Ratification of PricewaterhouseCoopers as auditor for FY2023: 17,879,658 for, 725 against.
- Quorum of 17,880,383 shares (81.55% of outstanding) present at the 2023 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000095017023029447/0000950170-23-029447-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000095017023029447/acrv-20230622.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-029447

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer